Evidence review
GLP-1 Itching and Rash: Which Kind You Have Decides What You Do About It
Sort it by mechanism, not severity. The reaction that means stop the drug can arrive with almost no itch at all.
On this page
Sort it first
Severity is the wrong triage question here, because the most serious reaction can arrive with barely any itch. Sort by what kind it is.
| What you have | Where / how it behaves | What to do |
|---|---|---|
| Injection-site irritation | At the needle site only, within hours, gone in a day or two | Rotate sites properly |
| Dry-skin itch | Diffuse, shins and forearms, worse after hot showers | Moisturize, cooler water, fluids |
| Hives (urticaria) | Raised welts that move around, come and go in hours | Contact your prescriber |
| Angioedema | Swelling of lips, tongue, face or throat, often little itch | Stop and seek help now |
That last row is the reason this page leads with sorting. The label's own instruction for a suspected hypersensitivity reaction is to discontinue and promptly seek medical advice — on suspicion, not confirmation.
The only labeled numbers you can actually use
Wegovy's label is close to silent here: across the whole prescribing information, "pruritus" appears once, and rash and urticaria appear only in the pediatric table (each 3% against 0% on placebo). There is no adult itching row to quote.
Zepbound's label does publish a usable figure, and it covers the commonest complaint:
| Zepbound | Placebo | 5 mg | 10 / 15 mg |
|---|---|---|---|
| Injection site reactions | 2% | 6% | 8% |
| Hypersensitivity reactions | 3% | 5% | 5% |
Injection-site reactions roughly triple to quadruple. Hypersensitivity reactions move from 3% to 5% and then stay flat across doses.
What the biggest dataset says, and the trap in it
A 2026 analysis of FDA adverse-event reports from 2018 to 2024 found cutaneous adverse events in up to 8.16% of GLP-1 cases, reported more often in females, mean age 601.
Two corrections belong with that number.
It is a share of reports, not of patients. That database has no denominator — it counts reports somebody chose to file, not people who took the drug. It cannot tell you your odds.
And the class compares well. Against DPP-4 inhibitors as a comparator, the proportional reporting ratio was 0.27 (95% CI 0.257–0.284) — proportionally fewer skin reports than the comparison class. Within GLP-1s, semaglutide had the highest rate and dulaglutide the lowest1. If that has you thinking about a switch, Zepbound vs Wegovy covers the trade, and the best GLP-1 for busy moms board scores which programs carry both molecules on one plan.
Fixes, by type
- Rotate sites, properly. Abdomen, thigh, upper arm — the label instructs rotating with each dose, and returning to the one spot that does not sting is the single most common cause of site itch. Where to inject a GLP-1 has the rotation rule for each drug, including the one that differs on Zepbound.
- Moisturize within three minutes of a shower, on skin still damp. Matters more than which product.
- Turn the water temperature down. Hot showers strip the barrier and are a very common trigger for the diffuse type.
- Drink more than you feel like. Appetite suppression cuts fluid intake as well as food, and mild dehydration itches.
- Check what else changed. Rapid loss changes how clothes sit, so a waistband now rubbing somewhere new produces an itch with no pharmacology in it.
- Check whether it is actually a skin-fold rash. Friction and moisture in folds after fast weight loss is a different problem with a different fix — the skin-fold rash after fast weight loss has it.
Call the same day if
- Swelling of the lips, tongue, face, eyelids or throat
- Any difficulty breathing or swallowing
- Hives spreading rapidly, or with dizziness or faintness
- A rash with blistering, peeling, or involving the mouth or eyes
- Itching with dark urine, pale stools, or yellowing of the eyes — that is a liver question, not a skin one
What is genuinely unknown
There is no published incidence for ordinary itching on these drugs in adults. The trials did not report it at a rate high enough to list, and the database that captures it cannot produce a rate. Reviews of the dermatologic literature describe a spread of findings rather than one syndrome2,3.
So if your prescriber cannot tell you how likely this was, that is not evasion. Nobody has the number.
Frequently asked questions
How common is a rash on a GLP-1?
There is no published adult incidence. Wegovy's label mentions pruritus once in the entire document and lists rash and urticaria only in its pediatric table, each at 3% against 0% on placebo. Zepbound does report injection site reactions, rising from 2% on placebo to 6% at 5 mg and 8% at higher doses.
When is a GLP-1 rash an emergency?
When it involves swelling of the lips, tongue, face, eyelids or throat, or any difficulty breathing or swallowing. That is angioedema, and it can arrive with very little itching, which is why sorting by severity is unreliable. The label instructs discontinuing on suspicion of a hypersensitivity reaction and seeking medical advice promptly.
How do I stop itching at my injection site?
Rotate sites properly. The label lists the abdomen, thigh and upper arm and instructs rotating with each dose, and going back to the one spot that does not sting is the most common cause. Site itch that appears within hours and settles within a day or two is the ordinary pattern.
Are skin reactions more common in women on GLP-1s?
They are reported more often in women. A FAERS analysis covering 2018 to 2024 found cutaneous events in up to 8.16% of GLP-1 cases, more often in females, mean age 60. That figure is a share of reports filed rather than of patients treated, so it describes who reports rather than how likely it is.
Is my rash from the drug or from losing weight quickly?
Worth distinguishing, because the fixes differ. Friction and moisture in skin folds after rapid weight loss is a mechanical problem treated by keeping the area dry and reducing rubbing. A drug-related itch or rash follows a different pattern — tied to the injection site, or diffuse and unrelated to where skin touches skin.
Where this leaves you
References
- Fat MN, Johnson HC, Farberg AS (2026). Cutaneous Adverse Events Associated With GLP-1 Receptor Agonists: A FAERS Database Analysis From 2018-2024 (spontaneous reporting database with no denominator; percentages refer to reports filed rather than patients treated). Journal of Drugs in Dermatology. https://pubmed.ncbi.nlm.nih.gov/41493256/
- Tran MM, Mirza FN, Lee AC, Goldbach HS, Libby TJ, Wisco OJ (2024). Dermatologic findings associated with semaglutide use: A scoping review. Journal of the American Academy of Dermatology. https://pubmed.ncbi.nlm.nih.gov/38554940/
- Salazar CE, Patil MK, Aihie O, Cruz N, Nambudiri VE (2024). Rare cutaneous adverse reactions associated with GLP-1 agonists: a review of the published literature. Archives of Dermatological Research. https://pubmed.ncbi.nlm.nih.gov/38795152/
Read this as information, not instructions. WorkingMomRx is educational and never a diagnosis, a treatment plan, or a reason to start or stop a medication. A GLP-1 is a clinical decision — run it past a licensed clinician who knows your history before you act on anything here.
Continue reading
The Skin-Fold Rash After Fast Weight Loss
A red, sore patch where skin meets skin. Where it actually appears, why losing weight tends to improve it, and what cleared it fastest in a trial.
ReadGLP-1 Side-Effect Quick-Fix Reference for Busy Patients
A scannable, cited reference to common GLP-1 side effects — nausea, constipation, reflux, fatigue — each with a fix and a when-to-call-your-doctor line.
ReadWhere to Inject a GLP-1: Sites, Rotation, and the Rule That Differs by Drug
Abdomen, thigh or upper arm — but Zepbound says the arm should be injected by someone else. Rotation rules, and why the site does not change absorption.
Read